Ancilia Biosciences, Inc., (Ancilia Bio), a biotechnology company harnessing the natural power of CRISPR to create bacterial therapies and products with immunity against destructive viruses, today announced the closing of a $4.2 million financing. The […]
SNIPR BIOME receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR Biome’s microbial gene therapy platform to improve Environmental Enteric Dysfunction (EED) in pregnant women from low- and middle-income […]
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it has entered into a non-binding memorandum of understanding with Nestlé Health Science for the sale of Seres’ VOWST assets that will provide […]
As the self-care movement drives consumers toward proactive health choices, the hunt for holistic well-being will stimulate innovations in the microbiome space. Scientific communities and consumers alike recognize the gut microbiome as an organ with […]
The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and […]
Lallemand Health Solutions and dsm-firmenich are joining forces to launch early-life synbiotic solutions, leveraging the synergy of probiotics and human milk oligosaccharides (HMOs). Unlocking the synergy between probiotics and HMOs to provide infants with the […]
SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, announces today that it has received $5.48 million from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (“CARB-X”) to […]
EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that the Company has completed its £27m ($34m USD) funding round, supported by new and existing investors. The funding will […]
The government of the Netherlands has allocated €200 million from the country’s National Growth Fund for a public-private consortium that will conduct research into ‘microbiomes’ and economically interesting applications thereof. The funds, which will add […]
Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, with participation of all existing investors, reflects enthusiasm for […]
BiomX Inc. (NYSE American: PHGE) (together with its subsidiaries and/or associates, “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a […]